Established and evolving medical therapies for claudication in patients with peripheral arterial disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 11, 2006, Pages 604-610

  Regensteiner, Judith G ^a,b   Stewart, Kerry J ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CARNITINE DERIVATIVE; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTOXIFYLLINE; PLACEBO; PROPIONYL CARNITINE; RAMIPRIL; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; SIMVASTATIN; UNCLASSIFIED DRUG;

ANKLE BRACHIAL INDEX; BLOOD PRESSURE MONITORING; CLAUDICATION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; ENDOVASCULAR SURGERY; FUNCTIONAL ASSESSMENT; GENE THERAPY; HEART FAILURE; HEMODYNAMICS; HUMAN; KINESIOTHERAPY; LEG REVASCULARIZATION; MENTAL HEALTH; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SOCIAL INTERACTION; SYMPTOM; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ANKLE; ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; BRACHIAL ARTERY; EXERCISE TEST; EXERCISE THERAPY; HEMATOLOGIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; VASODILATOR AGENTS;

EID: 33750402240     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0660     Document Type: Review

References (45)

1. Criqui MH et al. (1985) The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510-515
2. Hiatt WR et al. (1995) Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study. Circulation 91: 1472-1479
3. Criqui MH et al. (1997) The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 2: 221-226
4. Centers for Disease Control and Prevention (2005) Lower extremity disease among persons aged ≥40 years with and without diabetes - United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54: 1158-1160
5. Hiatt WR (2005) The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl 6: 21-31
6. Regensteiner JG and Hiatt WR (2002) Current medical therapies for patients with peripheral arterial disease: A critical review. Am J Med 112: 49-57
7. Hirsch AT et al. (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J AM Coll Cardiol 47: 1239-1312
8. Hirsch AT et al. (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324
9. Criqui MH et al. (1996) The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med 1: 65-71
10. Hiatt WR et al. (1990). Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 81: 602-609
11. Carter SA (1969) Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA 207:1869-1874
12. Hiatt WR et al. (1988) The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 12: 525-532
13. Labs KH et al. (1999) Reliability of treadmill testing in peripheral arterial disease: A comparison of a constant load with a graded load treadmill protocol. Vasc Med 4: 239-246
14. Regensteiner JG et al. (1996) Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 23: 104-115
15. Regensteiner JG et al. (2002) Effect of cilostazol on community-based walking ability and health-related quality of life in patients with peripheral arterial disease: Results of six randomized controlled trials. J Am Geriatr Soc 50: 1939-1946
16. McDermott MM et al. (1998) Measurement of walking endurance and walking velocity with questionnaire: Validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 28: 1072-1081
17. Regensteiner JG et al. (1993) Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology 44: 1-10
18. Porter JM et al. (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72
19. Dawson DL et al. (2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109: 523-530
20. Packer M et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure, The PROMISE Study Research Group. N Engl J Med 325: 1468-1475
21. The Scandinavian Simvastatin Survival Study group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
22. Mohler ER III et al. (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108: 1481-1486
23. McDermott MM et al. (2003) Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107: 757-761
24. Mondillo S et al. (2003) Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114: 359-364
25. Brevetti G et al. (1995) Propionyl-9 pt-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 26: 1411-1416
26. Hiatt WR et al. (2001) Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110: 616-622
27. Brevetti G et al. (1999) European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 34: 1618-1624
28. Khan TA et al. (2003) Gene therapy progress and prospects: Therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10: 285-291
29. Lederman RJ et al. (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359: 2053-2058
30. Rajagopalan S et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938
31. Ahimastos AA et al. (2006). Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease: A randomized trial. Ann Intern Med 144: 660-664
32. Horsch S and Walther C (2004) Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)-a review based on randomized, controlled studies. Int J Clin Pharmacol Ther 42: 63-72
33. Gardner AW and Poehlman ET (1995) Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 274: 975-980
34. Regensteiner JG (1997) Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc Med 2: 238-242
35. Robeer GG et al. (1998) Exercise therapy for intermittent claudication: a review of the quality of randomised clinical trials and evaluation of predictive factors. Eur J Vasc Endovasc Surg 15: 36-43
36. Leng GC et al. (2000) Exercise for intermittent claudication. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD000990
37. Tsai JC et al. (2002) The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med 252: 448-455
38. Stewart KJ et al. (2002) Exercise training for claudication. N Engl J Med 347: 1941-1951
39. Gardner AW et al. (2002) Effects of long-term exercise rehabilitation on claudication distances in patients with peripheral arterial disease: A randomized controlled trial. J Cardiopulm Rehabil 22: 192-198
40. Alpert JS et al. (1969) Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation 39: 353-359
41. Clifford PC et al. (1980) Intermittent claudication: Is a supervised exercise class worth while? Br Med J 280: 1503-1505
42. Gardner AW et al. (2000) Improved functional outcomes following exercise rehabilitation in patients with intermittent claudication. J Gerontol A Biol Sci Med Sci 55: M570-M577
43. Gibellini R et al. (2000) Exercise training in intermittent claudication. Int Angiol 19: 8-13
44. Wolosker N et al. (2003) Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. Arch Intern Med 163: 2296-2300
45. Izquierdo-Porrera AM et al. (2000) Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. J Vasc Surg 31: 670-677